Article
Pharmacology & Pharmacy
Shailly Mehrotra, Atul Bhattaram, Kevin Krudys, Michael Bewernitz, Ramana Uppoor, Mehul Mehta, Tao Liu, Philip Sheridan, Norman Hershkowitz, Nicholas Kozauer, Eric Bastings, Billy Dunn, Angela Yuxin Men
Summary: The US FDA has concluded that drugs approved for treating partial onset seizures in adults can be applied to pediatric patients aged one month and older, eliminating the need for independent efficacy trials. This study analyzes dosing, pharmacokinetic, exposure-response, and clinical data from eight approved drugs to support the extrapolation of efficacy in pediatric patients with partial onset seizures. The results show that based on disease similarity, response to treatment, and exposure-response relationships, the extrapolation of efficacy in pediatric patients aged one month and above is justified.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Clinical Neurology
Liyan Hou, Bingjie Peng, Defu Zhang, Jingjing Yang, Ying Wang, Li Tong, Sheng Li, Qingshan Wang, Jie Zhao
Summary: This study conducted a systematic review and meta-analysis on the safety and efficacy of Lacosamide as adjunctive treatment in adults with refractory epilepsy. The results showed that Lacosamide adjunctive therapy was effective and well tolerated in this patient population.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Siew-Na Lim, Tony Wu, Wei-En Johnny Tseng, Hsing- Chiang, Mei-Yun Cheng, Wey-Ran Lin, Chia-Ni Lin
Summary: Perampanel shows effectiveness and satisfactory safety profile in the emergency treatment of established refractory and super-refractory status epilepticus. Patients with unique types and causes of SE, particularly nonconvulsive status epilepticus, may have a better response to perampanel treatment.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Sandip Patel, Reid Grinspoon, Bradley Fleming, Lauren A. Skirvin, Christina Wade, Emma Wolper, Patricia L. Bruno, Elizabeth A. Thiele
Summary: CBD has been shown to maintain its efficacy in controlling seizures over a treatment period of up to 60 months, especially effective in controlling seizures in the setting of tuberous sclerosis complex and reducing epileptic spasms and absence seizures. CBD also remains effective over a broad dose range, with most subjects reducing the dose of at least one concomitant AED compared to baseline.
Review
Behavioral Sciences
Jose Carlos Estevez-Maria, Inigo Garamendi-Ruiz
Summary: This study aims to evaluate the efficacy and safety of perampanel in clinical practice in Europe. The results show that perampanel can effectively reduce seizures in some patients and is safe and reliable in clinical practice, although the incidence of adverse events is higher.
EPILEPSY & BEHAVIOR
(2022)
Review
Clinical Neurology
Alekhya Lavu, Laila Aboulatta, Ahmed M. Abou-Setta, Basma Aloud, Nicole Askin, Rasheda Rabbani, Walid Shouman, Ryan Zarychanski, Sherif Eltonsy
Summary: This systematic review examines the effectiveness and safety of Perampanel in treating epilepsy. The results show a significant reduction in seizures and a potential increase in discontinuations due to treatment-emergent adverse events (TEAEs). The most commonly reported TEAEs are non-threatening, but there is a possibility of rare but serious adverse psychological outcomes.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2022)
Article
Clinical Neurology
Paolo Bonanni, Antonio Gambardella, Paolo Tinuper, Benedetto Acone, Emilio Perucca, Giangennaro Coppola
Summary: Consensus was reached on the suitability of Perampanel as a first add-on based on its positive impact on quality of life, efficacy, tolerability, ease of use, and unique mechanism of action. However, potential unfavorable factors include slow dose titration, behavioral adverse effects, lack of safety information during pregnancy, and limited access to plasma Perampanel levels.
Article
Clinical Neurology
Elia M. Pestana Knight, Sam Amin, Nadia Bahi-Buisson, Tim A. Benke, J. Helen Cross, Scott T. Demarest, Heather E. Olson, Nicola Specchio, Thomas R. Fleming, Alex A. Aimetti, Maciej Gasior, Orrin Devinsky
Summary: This study evaluated the efficacy and safety of ganaxolone in patients with CDKL5 deficiency disorder (CDD) and refractory epilepsy. The results showed that ganaxolone significantly reduced seizure frequency in CDD patients and was generally well tolerated. The study suggests a potential treatment benefit for ganaxolone in CDD and further long-term treatment is being assessed in the ongoing open-label extension phase.
Article
Behavioral Sciences
Naoya Hasegawa, Jun Tohyama
Summary: The study evaluated irritability as a side effect in epilepsy patients receiving both levetiracetam (LEV) and perampanel (PER) therapy, finding that LEV and PER caused irritability in different patient groups. Irritability was associated with EEG findings of temporal focal epileptic discharge and higher dosages of LEV for LEV-related irritability, as well as with psychiatric comorbidity of irritability and EEG findings of nontemporal focal epileptic discharge for PER-related irritability.
EPILEPSY & BEHAVIOR
(2021)
Article
Clinical Neurology
Yaroslav Winter, Timo Uphaus, Katharina Sandner, Sven Klimpe, Sebastian von Stuckrad-Barre, Sergiu Groppa
Summary: Antiseizure medications acting through the slow inactivation of sodium channels, such as lacosamide and eslicarbazepine, show better tolerance and may be associated with improved seizure control in post-stroke epilepsy.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2022)
Review
Pediatrics
Ahmed Elmardenly, Zekra Aljehani, Abdullah Tamim, Anas Alyazidi, Osama Muthaffar
Summary: This study aimed to evaluate the safety and efficacy of perampanel (PER) as an adjuvant treatment for children with drug-resistant epilepsy. The results showed that PER demonstrated good effectiveness and tolerability in the treatment of drug-resistant epilepsy.
Article
Clinical Neurology
Pavel Klein, Sami Aboumatar, Christian Brandt, Fang Dong, Gregory L. Krauss, Sarah Mizne, Juan Carlos Sanchez-Alvarez, Bernhard J. Steinhoff, Vicente Villanueva
Summary: This study evaluated the long-term efficacy and safety of adjunctive cenobamate in the treatment of uncontrolled focal seizures. The results showed that cenobamate reduced seizure frequency and had a high retention rate over a 48-month period. No new safety concerns were identified. These findings highlight the potential clinical benefits of cenobamate in long-term management of patients with uncontrolled focal seizures.
Article
Clinical Neurology
Jacqueline M. Cohen, Silje Alvestad, Carolyn E. Cesta, Marte-Helene Bjork, Maarit K. Leinonen, Mette Norgaard, Kristjana Einarsdottir, Anders Engeland, Mika Gissler, Oystein Karlstad, Kari Klungsoyr, Ingvild Odsbu, Johan Reutfors, Randi M. Selmer, Torbjoern Tomson, Sinna Pilgaard Ulrichsen, Helga Zoega, Kari Furu
Summary: This study compares the safety of different antiseizure medications in monotherapy during pregnancy regarding the risk of major congenital malformations (MCMs). The study found that lamotrigine monotherapy does not significantly increase the risk of MCMs compared to pregnancies without antiseizure medication exposure. However, valproate and topiramate are associated with an increased risk of MCMs, while carbamazepine, oxcarbazepine, and levetiracetam do not pose an increased risk.
ANNALS OF NEUROLOGY
(2023)
Article
Chemistry, Analytical
Bruno Charlier, Albino Coglianese, Francesca Felicia Operto, Federica De Rosa, Francesca Mensitieri, Giangennaro Coppola, Amelia Filippelli, Fabrizio Dal Piaz, Viviana Izzo
Summary: Therapeutic drug monitoring is crucial for improving the quality of antiepileptic drug use, especially in specific clinical situations. A novel method for measuring perampanel concentration in plasma samples was developed and compared with a commercially available method, showing the potential for clinical routine use as an alternative to LC-MS/MS.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2021)
Article
Dermatology
Riko Asakawa, Youichi Ogawa, Eri Maejima, Akiko Honobe-Tabuchi, Takashi Okamoto, Hiroshi Mitsui, Yoshiyuki Kagawa, Shinji Shimada, Tatsuyoshi Kawamura
Summary: The most common treatment for patients with bullous pemphigoid is systemic corticosteroids. However, some antiepileptic drugs can reduce the effectiveness of corticosteroids.
JOURNAL OF DERMATOLOGY
(2022)
Article
Neurosciences
J. Neumann, D. Sanak, A. Tomek, M. Bar, R. Herzig, M. Kovar, R. Mikulik, P. Rekova, D. Souckova, O. Skoda, D. Skoloudik, M. Sramek, D. Vaclavik
Summary: The latest research findings and guideline recommendations have prompted the need for an update to the 2014 Czech national guidelines on the treatment of acute ischemic stroke with intravenous thrombolysis, in order to accommodate patients beyond the standard time window and with unknown time of stroke onset.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE
(2021)
Article
Cardiac & Cardiovascular Systems
Paula M. Janssen, Katrine van Overhagen, Jan Vinklarek, Bob Roozenbeek, H. Bart van der Worp, Charles B. Majoie, Michal Bar, David Cernik, Roman Herzig, Lubomir Jurak, Svatopluk Ostry, Robert Mikulik, Hester F. Lingsma, Diederik W. J. Dippel
Summary: This study assessed the between-center variation in functional outcome of patients with acute ischemic stroke who were treated with EVT and analyzed the extent to which this variation could be explained by modifiable center characteristics.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
(2022)
Article
Cardiac & Cardiovascular Systems
Robert Mikulik, Michal Bar, Silvie Belaskova, David Cernik, Jan Fiksa, Roman Herzig, Rene Jura, Lubomir Jurak, Lukas Klecka, Jiri Neumann, Svatopluk Ostry, Daniel Sanak, Petr Sevcik, Ondrej Skoda, Martin Sramek, Ales Tomek, Daniel Vaclavik
Summary: The study demonstrates that shortening the door-to-needle time (DNT) for intravenous thrombolysis can improve patient outcomes and reduce risks, specifically in terms of reducing the occurrence of intracerebral hemorrhage.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Clinical Neurology
Kamila Revendova, David Zeman, Pavlina Kusnierova, Radovan Bunganic, Pavla Hanzlikova, Katerina Karasova, Ondrej Volny, Michal Bar
Summary: This prospective cohort study did not demonstrate that intrathecal IgM synthesis is a risk factor for a second relapse or MRI activity, and it was not associated with higher disability in patients after the first demyelinating event.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Letter
Neurosciences
K. Revendova, M. Bar, O. Volny
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE
(2022)
Article
Multidisciplinary Sciences
R. Bunganic, S. Blahutova, K. Revendova, O. Zapletalova, P. Hradilek, R. Hrdlickova, A. Ganesh, Z. Cermakova, M. Bar, O. Volny
Summary: The study evaluated the clinical effect of therapeutic plasma exchange (TPE) in the treatment of relapse in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed a significant improvement in EDSS score after TPE, with better effectiveness observed in female patients.
SCIENTIFIC REPORTS
(2022)
Article
Clinical Neurology
K. Zondra Revendova, D. Zeman, R. Bunganic, K. Karasova, O. Volny, M. Bar, P. Kusnierova
Summary: This study compared the differences between SIMOA and hsELISA methods in determining serum neurofilament concentrations in MS patients, and identified factors that affect the accuracy of hsELISA measurements.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Behavioral Sciences
Kamila Zondra Revendova, Chiara Starvaggi Cucuzza, Ali Manouchehrinia, Mohsen Khademi, Michal Bar, David Leppert, Elisabeth Sandberg, Russell Ouellette, Tobias Granberg, Fredrik Piehl
Summary: Neurofilament light (NfL) levels can reflect inflammatory disease activity in multiple sclerosis (MS). However, it is unclear if NfL can also be a biomarker for MS progression in treated patients without relapses and focal lesion accrual. This study found that disease modulatory therapy can reinstate an age and sex pattern for cerebrospinal fluid NfL (cNfL) similar to that of control subjects in MS patients without signs of inflammatory disease activity. There was no significant association between cNfL levels and clinical worsening, disability level, or MRI metrics.
BRAIN AND BEHAVIOR
(2023)
Article
Mathematics
Martin Kotyrba, Hashim Habiballa, Eva Volna, Robert Jarusek, Pavel Smolka, Martin Prasek, Marek Malina, Vladena Jaremova, Jan Vantuch, Michal Bar, Petr Kulistak
Summary: This article focuses on the development of an expert system for neurocognitive rehabilitation. The unique approach of this interdisciplinary research is to adapt the expert system based on real patients' results from the ACE-R. The expert system allows for an automated optimized design of a neurorehabilitation plan using the CHC model, achieving an average error of 5.94% for all domains.
Article
Engineering, Biomedical
Martin Lachnit, Kamila Zondra Revendova, Pavel Hradilek, Radovan Bunganic, Zdenek Koristek, Tomas Jelinek, Monika Skutova, Radim Piza, Ondrej Volny, Roman Hajek, Michal Bar
Summary: This case series demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is a promising therapeutic approach to slow down the rapid progression of clinical disability in patients with multiple sclerosis (MS), with a good safety profile.
BIOMEDICAL PAPERS-OLOMOUC
(2023)
Article
Clinical Neurology
Vera Bril, Robert D. M. Hadden, Thomas H. Brannagan, Michal Bar, Elisabeth Chroni, Konrad Rejdak, Alberto Rivero, Henning Andersen, Norman Latov, Todd Levine, Mamatha Pasnoor, Sabrina Sacconi, Nizar Souayah, Colin Anderson-Smits, Kim Duff, Erin Greco, Shabbir Hasan, Zhaoyang Li, Leman Yel, Hakan Ay
Summary: The ADVANCE-CIDP 1 trial evaluated the efficacy and safety of facilitated subcutaneous immunoglobulin (fSCIG) in preventing relapse in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The results showed that fSCIG 10% was more effective than placebo in preventing CIDP relapse, with similar safety profiles between the two groups.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tomas Klail, Petra Sedova, Jan F. Vinklarek, Ingrid Kovacova, Michal Bar, Filip Cihlar, David Cernik, Lubomir Koci, Rene Jura, Roman Herzig, Jakub Husty, Martin Kocher, Martin Kovar, Miroslava Nevsimalova, Jan Raupach, Miloslav Rocek, Daniel Sanak, Petr Sevcik, David Skoloudik, Martin Sramek, Jiri Vanicek, Peter Vasko, Daniel Vaclavik, Ales Tomek, Robert Mikulik
Summary: Baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT) did not improve functional independence or increase the risk of intracranial hemorrhage (ICH).
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Meeting Abstract
Clinical Neurology
K. Revendova, P. Kusnierova, K. Karasova, R. Bunganic, P. Hradilek, O. Volny, M. Bar
MULTIPLE SCLEROSIS JOURNAL
(2022)
Review
Neurosciences
Daniel Vaclavik, Ondrej Volny, Petra Cimflova, Krystof Svub, Katerina Dvornikova, Michal Bar
Summary: Computed tomography perfusion (CTP) is a functional examination that evaluates cerebral perfusion and improves diagnostic accuracy of ischemic stroke. It has been shown to benefit patients with anterior circulation stroke, allowing treatment referral outside the time window for thrombolysis or thrombectomy. Additionally, CTP plays a role in the diagnosis of stroke mimics.
JOURNAL OF INTEGRATIVE NEUROSCIENCE
(2022)
Article
Psychology, Multidisciplinary
Radka Buzgova, Radka Kozakova, Michal Bar, Monika Skutova, Pavel Ressner, Petra Bartova
Summary: The study identified differences in attitudes towards end-of-life care between patients with progressive neurological diseases and their family members. Family members tended to favor keeping patients alive at any cost, while patients preferred to have control over their end-of-life. Doctors were the most frequently consulted decision-makers, and both patients and family members desired written records to guide treatment decisions.
OMEGA-JOURNAL OF DEATH AND DYING
(2022)